Empowering Patients and Prescribers to Improve Treatment Adherence in Schizophrenia.

Slides:



Advertisements
Similar presentations
Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice.
Advertisements

Symptom Control and Enhancing Functioning in Schizophrenia
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Clinical Trials in IBD.
This program will include a discussion of off-label treatment not approved by the FDA for use in the United States.
Why New Treatments for Schizophrenia Should Be on Your Radar
Silverdale Medical Practice
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.
Advances in Managing Inhibitors in Patients With Hemophilia A
Thrombosis, Cancer, and NOACs
Addressing Cognitive and Psychiatric Effects of Antiepileptic Drugs
Access to NOAC Therapy:
The Nurse View.
Progression After Cancer Immunotherapy in Advanced NSCLC
The HCV Revolution: Are You and Your Practice Ready?
Epidemiology Venous Pathophysiology Etiology.
PCP Perspectives Clinical Considerations in Hyperkalemia
Before and After: Patient Cases in Onychomycosis
Surveying the Safety of NOACs in the Real World
Selecting NOACs for High-Risk Patients
Optimizing Patient Outcomes in IBD
Chronic Idiopathic Urticaria
Treatment of Generalized Tonic-Clonic Seizures in the Modern Era
AGHPS November 9th 2012.
What Is a Biosimilar?. Biosimilar Application in RA Clinical Practice: Current Knowledge and New Data  
Access to NOAC Therapy:
Evaluating Next-Generation BTK Inhibitors
Watching for the Patient With AF: Latest Advances and Technologies
Gene Therapy: Past, Present, and Future
Oral Anticoagulation in AF
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Ask the Experts.
A Primer on Medication Delivery Systems in COPD Management
Immunotherapy for cSCC
Perspectives on the Impact of Inflammation in OA
When Is Biologic Therapy Appropriate for HS?
Introduction. Clinical Scenario: Encouraging Adherence in Patients with Schizophrenia.
NOACs in AF: Consequences of Underdosing and NonAdherence
Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials
Parkinson Disease Psychosis
Talking With Your Patients About Excessive Sweating
A Primer on Medication Delivery Systems in COPD Management
Treatment-Resistant Schizophrenia
Guide to Atopic Dermatitis
Application of Biosimilars in RA IN Clinical Practice: Key Issues and Challenges  
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Patient-Centered Management in BRAF-Positive Metastatic Melanoma
EGPA.
Breaking News in Pemphigus Vulgaris and the Latest Updates for Your Practice.
Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC
Patient Questions and Expert Answers in Psoriasis:
Insulin in Diabetes Management: Effective Patient Selection Is Key
The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.
Optimizing Joint Health in Hemophilia
Critical Decision Points in Insomnia
The Psychiatrist's Role in Tardive Dyskinesia
A Nursing Perspective on Improving Outcomes for Patients With Hemophilia.
Incorporating Prostacyclins Into Practice
NOACs in AF: Consequences of Underdosing and NonAdherence
Improving Adherence to Antiplatelet Therapy After an ACS Event
When Good Isn't Good Enough
Managing Pain in the 21st Century
The Psychiatrist's Role in Tardive Dyskinesia
This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.
Evaluating the Science of Cardiogenic Shock
Patient and Clinician Perspectives on Preventive Therapy for Migraine
Pulmonary Arterial Hypertension and Hospitalizations
Expert Insights in Diagnosis and Management of Common Drug-Induced Movement Disorders.
Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure
What's New in NOACs in AF?.
Presentation transcript:

Empowering Patients and Prescribers to Improve Treatment Adherence in Schizophrenia

Introduction

Hospitalization Rate Meta-Analysis Long-Acting Injectables vs Oral Antipsychotic

Swedish Registry: Mortality Risk LAIs and Oral Antipsychotics

Recent Online Survey Persons With Lived Experience and Caretakers

Psychiatrists Attitudes Long-Acting Injectables

Real-World Data: PRELAPSE Trial

Real-World Data: PRELAPSE Trial Findings

LAI Antipsychotics Second-Generation Agents

Understanding Adverse Event History Expert Consensus Survey

LAI Antipsychotics First-Generation Dosing Overview

LAI Characteristics and Properties Prescribing Considerations

FDA-Approved LAIs for Schizophrenia Characteristics of First- and Second-Generation LAIs

Discussing LAI Options: Considering the Experience of the Person With Lived Experience and Their Family

LAI Selection Factors Expert Consensus Survey

Summary of Recommendations Expert Consensus Survey

Shared Decision Making

Patient Preference Discussion Considering an LAI

Multidisciplinary Team Needs to Be Aligned

Multidisciplinary Team Education

Concise Communication and Education

Use of LAIs Clinical Insights

Evolution of Opinions Who Are Candidates for LAI Antipsychotics?

Concluding Remarks

Lived Experience With Schizophrenia Q&A

Can you tell us what is the most difficult or frustrating aspect of managing your experience with schizophrenia?

Was there anything regarding treatment that was problematic and would be best to avoid?

What is it like to take medications for schizophrenia?

Can you talk about your experience with long acting, injectable medication?

What has been the most difficult aspect of treatment for you?

How did you get help with this aspect?

Was there anyone in particular on the team that was able to help?

How were they able to help? What did they do?

Other than medications, what did you find helpful?

What advice would you like to give to providers?

What is the best way to include family?

What is the best way to include members of the treatment team?

Abbreviations